Experimental gene therapy aims to beat hepatitis B by silencing viral DNA

An experimental therapy called CRMA-1001 takes a new approach to hepatitis B: instead of attacking the virus directly, it silences the viral DNA. This matters because current treatments rarely eliminate that DNA, which allows the virus to bounce back after therapy. By muting the DNA itself, the experimental approach is being seen as a promising development against the infection.